Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

597 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Use of defibrotide in COVID-19 pneumonia: comparison of a phase II study and a matched real-world cohort control.
Ruggeri A, Corrado F, Voza A, Wei LJ, Catalano G, Liberatore C, Nitti R, Fedeli C, Bruno A, Calabretta E, Giglio F, Sciutti F, Lunghi F, Landoni G, Aghemo A, Iacobelli M, Querini PR, Richardson PG, Assanelli A, Peccatori J, Ciceri F, Carlo-Stella C. Ruggeri A, et al. Among authors: richardson pg. Haematologica. 2024 Oct 1;109(10):3261-3268. doi: 10.3324/haematol.2024.285345. Haematologica. 2024. PMID: 38779740 Free PMC article. Clinical Trial.
Defibrotide for Protecting Against and Managing Endothelial Injury in Hematologic Malignancies and COVID-19.
Richardson E, Mo CC, Calabretta E, Corrado F, Kocoglu MH, Baron RM, Connors JM, Iacobelli M, Wei LJ, Benjamin EJ, Rapoport AP, Díaz-Ricart M, Martínez-Mellado AJ, Carlo-Stella C, Richardson PG, Moraleda JM. Richardson E, et al. Among authors: richardson pg. Biomolecules. 2025 Jul 14;15(7):1004. doi: 10.3390/biom15071004. Biomolecules. 2025. PMID: 40723876 Free PMC article. Review.
Defibrotide improves COVID-19-related acute respiratory distress syndrome in myeloma patients after chimeric antigen receptor T-cell treatment without compromising virus-specific and anti-myeloma T-cell responses.
Kocoglu MH, Richardson PG, Mo CC, Rapoport AP, Atanackovic D. Kocoglu MH, et al. Among authors: richardson pg. Haematologica. 2024 Jul 1;109(7):2372-2377. doi: 10.3324/haematol.2023.284793. Haematologica. 2024. PMID: 38385273 Free PMC article. No abstract available.
Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study.
Richardson PG, Jagannath S, Moreau P, Jakubowiak AJ, Raab MS, Facon T, Vij R, White D, Reece DE, Benboubker L, Zonder J, Tsao LC, Anderson KC, Bleickardt E, Singhal AK, Lonial S; 1703 study investigators. Richardson PG, et al. Lancet Haematol. 2015 Dec;2(12):e516-27. doi: 10.1016/S2352-3026(15)00197-0. Epub 2015 Nov 16. Lancet Haematol. 2015. PMID: 26686406 Free PMC article. Clinical Trial.
Defibrotide for prophylaxis of sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) in pediatric high-risk patients: consensus guidelines from the European Society for Blood and Marrow Transplantation (EBMT).
Corbacioglu S, Bajwa R, Antmen AB, Balduzzi A, Boelens JJ, Bonifazi F, Cesaro S, Ciceri F, Colecchia A, Dignan F, Kleinschmidt K, Mahadeo KM, Pagliuca A, Sedlacek P, Shaw PJ, Stein J, Szmit Z, Tambaro F, Ince E, Verna M, Yesilipek A, Zecca M, Richardson PG, Mohty M, Kalwak K; EBMT Paediatric Diseases Working Party. Corbacioglu S, et al. Among authors: richardson pg. Bone Marrow Transplant. 2026 Jan 13. doi: 10.1038/s41409-025-02793-x. Online ahead of print. Bone Marrow Transplant. 2026. PMID: 41530538
Mezigdomide for multiple myeloma: a focus on phase 2 trial data.
Mo CC, Liu Y, Nadeem O, Midha S, Laubach JP, Salman TJ, Nicholson T, Donnelly K, Bianchi G, Sperling AS, Hartley-Brown MA, Richardson PG. Mo CC, et al. Among authors: richardson pg. Expert Opin Emerg Drugs. 2025 Oct 30:1-11. doi: 10.1080/14728214.2025.2575570. Online ahead of print. Expert Opin Emerg Drugs. 2025. PMID: 41163399 Review.
The Role of CELMoD Agents in Multiple Myeloma.
van de Donk NWCJ, Bahlis NJ, Pawlyn C, Gay F, Mateos MV, Weisel K, Lonial S, Richardson PG. van de Donk NWCJ, et al. Among authors: richardson pg. Onco Targets Ther. 2025 Aug 27;18:921-933. doi: 10.2147/OTT.S398118. eCollection 2025. Onco Targets Ther. 2025. PMID: 40901494 Free PMC article. Review.
597 results